The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Challenges and opportunities for patients with advanced NSCLC
Solange Peters, MD, PhD from the University of Lausanne, Lausanne, Switzerland discusses the challenges and opportunities in the second-line setting for patients with advanced non-small cell lung cancer (NSCLC). The challenge in treating patients with advanced NSCLC is deciding how to sequence the multiple different therapies, and developing the criteria that defines how physicians will make treatment choices. The ALEX study investigated the efficacy of alectinib compared to crizotinib in patients with advanced NSCLC, utilizing progression-free survival as an endpoint (NCT02075840). This interview was recorded at the annual meeting of European Lung Cancer Conference (ELCC) 2017 in Geneva, Switzerland.
